Mural Oncology (NASDAQ:MURA – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($2.01) EPS for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05), RTT News reports.
Mural Oncology Price Performance
Mural Oncology stock traded up $0.17 during mid-day trading on Tuesday, reaching $3.80. 146,728 shares of the company were exchanged, compared to its average volume of 162,217. The firm has a market cap of $64.68 million, a PE ratio of -0.42 and a beta of 3.66. The company has a fifty day simple moving average of $3.83 and a 200-day simple moving average of $3.58. Mural Oncology has a 12 month low of $2.87 and a 12 month high of $5.46.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Mural Oncology in a research note on Monday, November 11th.
About Mural Oncology
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Read More
- Five stocks we like better than Mural Oncology
- Russell 2000 Index, How Investors Use it For Profitable Trading
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- 3 Stocks to Consider Buying in October
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- How Technical Indicators Can Help You Find Oversold Stocks
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
